Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. November 2013 06:30 ET | Quelle: Coronado Biosciences

Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Discontinue Falk Phase 2 Trial of TSO in Crohn's Disease

BURLINGTON, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
06. November 2013 06:30 ET | Quelle: Coronado Biosciences

Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer

BURLINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
01. November 2013 08:00 ET | Quelle: Coronado Biosciences

Coronado Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2013

BURLINGTON, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
14. Oktober 2013 08:30 ET | Quelle: Coronado Biosciences

Coronado Biosciences Announces Top-Line Results From Its TRUST-I Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease

BURLINGTON, Mass., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
12. September 2013 07:30 ET | Quelle: Coronado Biosciences

Coronado Biosciences Announces Initiation of Phase 2 Study Evaluating TSO in Ulcerative Colitis

BURLINGTON, Mass., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
03. September 2013 08:30 ET | Quelle: Coronado Biosciences

Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences

BURLINGTON, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
27. August 2013 08:30 ET | Quelle: Coronado Biosciences

Coronado Biosciences to Participate in Citi's 8th Annual Biotech Conference

BURLINGTON, Mass., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
20. August 2013 08:30 ET | Quelle: Coronado Biosciences

Coronado Biosciences to Present at the Upcoming Themes in Helminth Biology Scientific Conference

BURLINGTON, Mass., Aug. 20, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
05. August 2013 07:00 ET | Quelle: Coronado Biosciences

Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2013

BURLINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
01. August 2013 08:30 ET | Quelle: Coronado Biosciences

Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences

BURLINGTON, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...

Nächste Seite